Novartis looks set to gain the first ever radiopharmaceutical approval in a frontline setting after Lutathera achieved success in a Phase III study in pancreatic cancer.
The Swiss pharma giant has reported that the NETTER-2 trial met its primary endpoint of improvement in progression-free survival (PFS) and the key secondary endpoint of objective response rate in patients with Grade 2 and 3 advanced newly diagnosed somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) after first-line treatment with
That makes Lutathera the first radioligand therapy (RLT) to demonstrate what the company said was a “clinically meaningful” benefit in a first-line setting